

### **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the Application:

#### **Listing of Claims**

1. (Currently amended) A non-invasive method for treating an ophthalmologic condition, the method comprising steps of:
  - providing a contact lens;
  - providing ~~a pharmaceutical composition suitable for ocular administration, wherein the pharmaceutical composition~~ eye drops comprising ~~comprises~~ an effective amount of hyaluronidase and collagenase;
  - applying the contact lens to an eye of a patient suffering from an ophthalmologic condition;
  - and
  - applying the ~~pharmaceutical composition~~ eye drops to the eye of the patient;  
wherein the ophthalmologic condition is a condition involving an error in the refraction of the eye, and whereby the treatment results in a correction of the ophthalmologic condition.
2. (Currently amended) A non-invasive method for treating an ophthalmologic condition by inducing changes in the physiology and anatomy of cornea, the method comprising steps of:
  - inducing a change in the corneal power by using molding contact lenses and a ~~pharmaceutical composition~~ eye drops by changing the radius of curvature of the anterior surface of both eyes[.];
  - wherein the ~~eye drops comprise pharmaceutical composition~~ comprises an effective amount of hyaluronidase and collagenase;  
wherein the ophthalmologic condition is a condition involving an error in the refraction of the eye, and whereby the treatment results in a correction of the ophthalmologic condition.
3. (Currently amended) A non-invasive method for treating an ophthalmologic condition by inducing changes in the physiology and anatomy of cornea, the method comprising steps of:

inducing a change in the corneal power by using molding contact lenses and a ~~pharmaceutical composition~~ eye drops by changing the radius of curvature of the anterior surface in only one eye[.];

wherein the eye drops ~~comprise a pharmaceutical composition~~ comprises an effective amount of hyaluronidase and collagenase;

wherein the ophthalmologic condition is a condition involving an error in the refraction of the eye, and whereby the treatment results in a correction of the ophthalmologic condition.

4. (Withdrawn and currently amended) A non-invasive method for the treatment of an ophthalmologic condition by inducing changes in the physiology and anatomy of cornea, the method comprising steps of:

calculating the corneal power considering the sphere (myopia) and cylinder (astigmatism) myopics within a range to be able to correct the near vision without diminishing substantially the far vision;

considering the best axis of astigmatism for each eye that a patient requires for the near vision so that the change induced in the corneal power along with its axis will be that required for the visual system of the patient;

allowing the patient to guide the necessary changes in the corneal power whereby good near vision is obtained;

using the molding contact lenses to change the surface of the cornea; and

administering eye drops ~~a pharmaceutical composition~~ to the eye, wherein the eye drops ~~comprise composition~~ comprises an effective amount of hyaluronidase and collagenase;

wherein the ophthalmologic condition is a condition involving an error in the refraction of the eye, and whereby the treatment results in a correction of the ophthalmologic condition.

5. (Withdrawn) The method of claim 4, wherein the sphere (myopia) ranges from -0.100 D to -0.999 D.

6. (Withdrawn) The method of claim 4, wherein the cylinder (astigmatism) ranges from

-0.100 D to -0.999 D.

7. (Withdrawn) The method of claim 4, wherein the hypermetropia ranges from +0.100 D to +0.999 D, and the cylinder (astigmatism) ranges from -0.100 D to -0.999 D.

8. (Original) The method of claim 1, 2, 3, or 4, wherein the contact lenses are commercially available.

9. (Original) The method of claim 1, 2, 3, or 4, wherein the contact lens is not custom made.

10. (Original) The method of claim 1, 2, 3, or 4, wherein the contact lens is not specially designed for orthokeratology.

11. (Original) The method of claim 1, 2, 3, or 4, wherein the contact lens is an extended wear contact lens.

12. (Currently amended) The method of claim 1, 2, 3, or 4, wherein the ~~pharmaceutical composition~~ eye drops further ~~comprises~~ comprise at least one agent selected from the group consisting of ~~other~~ enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasoconstrictors, ~~antileukal agents~~, anti-viral agents, anti-fungal agents, anti-inflammatory agents, and lubricants.

13. (Currently amended) The method of claim 1, 2, 3, or 4, wherein the ~~pharmaceutical composition~~ further ~~comprises~~ eye drops further comprise a polymer.

14. (Previously presented) The method of claim 13, wherein the polymer is selected from the group consisting of methylcellulose, cellulose, polyvinylalcohol, and polyethylene glycol.

15. (Withdrawn and currently amended) The method of claim 1, 2, 3, or 4, wherein the eye drops are in the form of pharmaceutical composition is a liquid.

16. (Currently amended) The method of claim 1, 2, 3, or 4, wherein the eye drops are pharmaceutical composition is in the form of a gel.

17. (Withdrawn and currently amended) The method of claim 1, 2, 3, or 4, wherein the eye drops are pharmaceutical composition is hypertonic.

18. (Currently amended) The method of claim 1, 2, 3, or 4, wherein the eye drops are pharmaceutical composition is hypotonic.

19. (Original) The method of claim 1, 2, 3, or 4, whereby the treatment results in correction of the ophthalmologic condition for at least 7 days.

20. (Original) The method of claim 1, 2, 3, or 4, whereby the treatment results in the correction of the ophthalmologic condition for at least 6 months.

21. (Previously presented) The method of claim 1, 2, 3, or 4, whereby the treatment results in the correction of the ophthalmologic condition for at least 1 year.

22. (Original) The method of claim 1, 2, 3, or 4, whereby the treatment results in the correction of up to 3 diopters of refractive error without surgery.

23. (Original) The method of claim 1, 2, 3, or 4, whereby the treatment results in the correction of up to 4 diopters of refractive error without surgery.

24. (Original) The method of claim 1, 2, 3, or 4, wherein the ophthalmologic condition is presbyopia.

25. (Withdrawn) The method of claim 1, 2, 3, or 4, wherein the ophthalmologic condition is myopia.

26. (Withdrawn) The method of claim 1, 2, 3, or 4, wherein the ophthalmologic condition is hyperopia.

27. (Withdrawn) The method of claim 1, 2, 3, or 4, wherein the ophthalmologic condition is astigmatism.

28-38. (Canceled)

39. (Withdrawn and currently amended) The method of claim 1, 2, 3, or 4 wherein the ~~composition further comprises~~ eye drops further comprise at least two agents selected from the group consisting of ~~ether~~ enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasoconstrictors, ~~antileukal agents~~, anti-viral agents, anti-fungal agents, anti-inflammatory agents, and lubricants.

40. (Canceled)

41. (Withdrawn and currently amended) The method of claim 1, 2, 3, or 4 wherein the ~~composition further comprises~~ eye drops further comprise at least three agents selected from the group consisting of ~~ether~~ enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasoconstrictors, ~~antileukal agents~~, anti-viral agents, anti-fungal agents, anti-inflammatory agents, and lubricants.

42. (Withdrawn and currently amended) The method of claim 1, 2, 3, or 4 wherein the ~~composition further comprises~~ eye drops further comprise at least four agents selected from the group consisting of ~~ether~~ enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents,

carbamide, cytokinases, vasoconstrictors, ~~anti-ocular agents~~, anti-viral agents, anti-fungal agents, anti-inflammatory agents, and lubricants.

43. (Withdrawn and currently amended) The method of claim 1, 2, 3, or 4, wherein the ~~composition comprises~~ eye drops comprise about 0.1% to about 5% hyaluronidase; about 0.1% to about 6% collagenase; and, optionally, a polymer selected from the group consisting of cellulose, methylcellulose, polyvinylalcohol, and polyethylene glycol.

44. (Withdrawn and currently amended) The method of claim 43, wherein the eye drops are ~~composition is~~ hypotonic.

45. (Withdrawn and currently amended) The method of claim 43, wherein the eye drops are ~~composition is~~ hypertonic.

46. (Withdrawn and currently amended) The method of claim 43, wherein the ~~composition further comprises~~ eye drops further comprise at least one agent selected from the group consisting of ~~other~~ enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasoconstrictors, ~~anti-ocular agents~~, anti-viral agents, anti-fungal agents, anti-inflammatory agents, and lubricants.

47-49. (Canceled)

50. (Withdrawn and currently amended) The method of claim 1, 2, 3, or 4 [[15]], wherein the eye drops are liquid ~~is in the form of a spray or in the form of eye drops~~.

51. (Previously presented) The method according to claim 16, wherein the gel is a semi-solid gel.

52. (Previously presented) The method according to claims 1, 2, 3 or 4, wherein the contact lens is a gas permeable contact lens.

53. (Currently amended) A non-invasive method for treating presbyopia, the method comprising steps of:

providing a contact lens;

providing a ~~pharmaceutical composition suitable for ocular administration, wherein the pharmaceutical composition comprises~~ eye drops comprising an effective amount of hyaluronidase and collagenase;

applying the contact lens to an eye of a patient suffering from presbyopia; and

applying the ~~pharmaceutical composition~~ eye drops to the eye of the patient;

whereby the treatment results in a correction of the presbyopia.